Primary treatment of advanced ovarian cancer: how does the 'real world' practice?
Aims: This study evaluated primary treatment modalities in advanced ovarian cancer according to sociodemographic characteristics and characterized chemotherapy regimens used. Methods: This was a retrospective study of newly diagnosed advanced ovarian, tubal or peritoneal cancer patients at two hospitals from 2011 to 2016. Results: Of 175 women, 41% received neoadjuvant chemotherapy and 59% received primary cytoreductive surgery. Within the neoadjuvant chemotherapy group, 23% did not have a surgical consultation prior to initiating treatment. Women receiving neoadjuvant chemotherapy lived closer to an academic center and more frequently received carboplatin/paclitaxel every 3 weeks. Cytoreductive surgery patients more frequently received intraperitoneal chemotherapy. Conclusion: The authors identified disparities in age, insurance, distance from treatment center and chemotherapy choice in the primary treatment for ovarian cancer.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
ISSN
Publication Date
Volume
Issue
Start / End Page
Related Subject Headings
- Retrospective Studies
- Progression-Free Survival
- Practice Patterns, Physicians'
- Paclitaxel
- Ovary
- Ovarian Neoplasms
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoadjuvant Therapy
- Middle Aged
Citation
Published In
DOI
EISSN
ISSN
Publication Date
Volume
Issue
Start / End Page
Related Subject Headings
- Retrospective Studies
- Progression-Free Survival
- Practice Patterns, Physicians'
- Paclitaxel
- Ovary
- Ovarian Neoplasms
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoadjuvant Therapy
- Middle Aged